Formycon AG (FRA:FYB) Other Financing: €54.98 Mil (TTM As of Dec. 2025)


FRA:FYB Formycon AG FRA:FYB
60 GF Score
Price €18.52
GF Value €36.30
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Formycon AG Other Financing?

Formycon AG FRA:FYB -2.11% 60 Other Financing is €54.98 Mil as of Dec. 2025. GuruFocus rates FRA:FYB with a GF Score™ of 60/100 and a GF Value™ of €36.30 (Possible Value Trap). The stock has 5 warning signs investors should review.

Formycon AG's Other Financing for the six months ended in Dec. 2025 was €58.47 Mil.

Formycon AG's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €54.98 Mil.

Formycon AG Other Financing Historical Data

* Premium members only.

The historical data trend for Formycon AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formycon AG Other Financing Chart

Formycon AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.23 39.88 -24.94 -42.20 54.80

Formycon AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.04 -25.61 -16.59 -3.50 58.47
FRA:FYB
60GF Score
Formycon AG FRA:FYB
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Formycon AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €54.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €54.98 Mil mean?
Formycon AG (FRA:FYB) has a Other Financing of €54.98 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Formycon AG and its competitors.
Is Formycon AG's Other Financing too high?
Formycon AG's current Other Financing is €54.98 Mil. Overall, Formycon AG has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's Other Financing compare to VRTX and REGN?
Formycon AG's Other Financing of €54.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Formycon AG and its competitors. Formycon AG's current Other Financing is €54.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Based on GuruFocus' analysis, Formycon AG (FRA:FYB) is currently considered Possible Value Trap. The stock's GF Value™ is €36.30, compared to a current price of €18.52 — trading 49% below its estimated fair value. The current Other Financing is €54.98 Mil. Formycon AG's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Formycon AG (FRA:FYB), the current Other Financing is €54.98 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formycon AG (FRA:FYB) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €18.52 is trading 49% below its estimated GF Value™ of €36.30. GuruFocus considers Formycon AG to be Possible Value Trap.

Key valuation signals for FRA:FYB:

  • Other Financing: €54.98 Mil
  • GF Value™: €36.30 vs. price of €18.52 (49% below fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the FRA:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
60GF Score

Get the complete analysis for FRA:FYB

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.52
Price
€36.30
GF Value